The results of a clinical trial on the drug semaglutide in teens, released in the New England Journal of Medicine, turned out to be better than anything the participants — or even the researchers — expected.
Channavix Therapeutics and Peregrine BioVentures are developing two patent families related to long-lasting, non-opioid, non-addictive pain therapeutics.
The UB researchers who have changed the way concussions are treated have been awarded a grant to conduct a clinical trial to take their Buffalo Concussion Protocol and apply it to the military environment.
UB researchers working alongside people with MS and their advocates have developed solutions that can open the door to better patient understanding about brain atrophy and potentially, better self-care.